

REMARKS

Claims 10-20 were examined. Claims 10, 14, and 18 are amended. Claims 10-20 remain in the Application.

A. Claims Rejected under 35 U.S.C. §103(a)

The Patent Office rejects claims 10-20 under 35 U.S.C. §103(a) as being anticipated by (GB2320190) of Chein (Chein). In dependent claims 1, 14, and 18 each relate to a kit comprising various hormones. As amended, each kit also includes a regimen for administration of the various hormones for reducing symptoms commonly associated with multiple sclerosis. Support for this amendment may be found in the Application at, for example, page 17, line 21 through page 18, line 4, where a patient is prescribed a regimen featuring twice daily subcutaneous doses of human growth hormone in an amount of 0.5 milligrams per dose along with testosterone, melatonin, DHEA, thyroid, pregnenolone, and thymus hormone to optimal levels.

Claims 10-20 are not obvious over Chein, because Chein does not describe a kit including a regimen for administration of hormones for reducing symptoms commonly associated with multiple sclerosis. In one aspect, Chein deals with administering hormones as anti-aging treatments and notes that hormone administration is also used in connection with certain degenerative diseases, often associated with hormonal deficiencies due to aging. As the Application notes at page 1, line 17-18, multiple sclerosis is not a disease associated with degenerative conditions associated with old age. Accordingly, there is no motivation in Chein to provide a regimen for administration of various hormones for reducing symptoms commonly associated with multiple sclerosis.

For the above stated reasons, claims 10-20 are not obvious over Chein. Applicant respectfully requests that the Patent Office withdraw the rejection to claims 10-20 under 35 U.S.C. § 103(a).

CONCLUSION

In view of the foregoing, it is believed that all claims now pending (1) are in proper form, (2) are neither obvious nor anticipated by the relied upon art of record, and (3) are in condition for allowance. A Notice of Allowance is earnestly solicited at the earliest possible date. If the Patent Office believes that a telephone conference would be useful in moving the Application forward to allowance, the Patent Office is encouraged to contact the undersigned at (310) 207-3800.

If necessary, the Commissioner is hereby authorized in this, concurrent and future replies, to charge payment or credit any overpayment to deposit account 02-2666 or any additional fees required under 37 C.F.R. §§ 1.16 or 1.17, particularly, extension of time fees.

Respectfully submitted,

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP

Dated: 6/10/05

William T. Babbitt

William Thomas Babbitt, Reg. No. 39,591

12400 Wilshire Boulevard
Seventh Floor
Los Angeles, California 90025
(310) 207-3800

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nedy Calderon
Nedy Calderon

6/10/05
Date